Know Cancer

forgot password

A Phase 1, Open Label, Multicenter Study of ACY-1215 in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma

Phase 1
18 Years
Open (Enrolling)
Multiple Myeloma

Thank you

Trial Information

A Phase 1, Open Label, Multicenter Study of ACY-1215 in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma

Inclusion Criteria:

- Relapsed or Relapsed/Refractory MM with progressive disease (PD) according to IMWG.

- Received at least 1 prior line of therapy for MM

- Not a candidate for autologous stem cell transplant (ASCT) or declined option.

- Karnofsky Performance Status score ≥ 70

- Adequate bone marrow reserve as evidenced by ANC > 1.0x109/L;Platelet > 50x109/L

- Creatinine Clearance of ≥ 60 mL/min

- Adequate hepatic function as evidenced by serum bilirubin values < 2.0 mg/dL; ALT
and/or AST < 3xULN.

- Corrected serum calcium ≤ ULN

- Able to take acetylsalicylic acid (ASA) (81 or 325 mg) daily as prophylactic
anticoagulation. Coumadin will be allowed provided the patient is fully
anticoagulated, with an INR of 2 or 3.

- Agreement to participate in RevAssist® Program

- Female of childbearing potential must have a negative pregnancy test 10-14 days prior
to and again within 24 hours of prescribing lenalidomide for Cycle 1 and must either
commit to continued abstinence or begin TWO acceptable methods of birth control.

- If male, including those who have had a vasectomy, must agree to use a latex condom
during any sexual contact with a female of childbearing potential.

Exclusion Criteria:

- Received any of the following antitumor therapies

- Radiotherapy or systemic therapy within 2 weeks of Cycle 1 Day 1 (C1D1)

- Investigational or biologic therapies within 3 weeks of C1D1

- Prior peripheral ASCT within 12 weeks of C1D1

- Prior allogeneic stem cell transplant

- Prior treatment with a histone deacetylase (HDAC) inhibitor

- Presence of an active systemic infection requiring treatment.

- History of other malignancies unless the patient has undergone definitive treatment
more than 5 yr prior, excluding basal cell carcinoma of the skin; superficial
carcinoma of the bladder; carcinoma of the prostate with current prostat specific
antigen < 0.1 ng/mL; ductal carcinoma in situ; or cervical intraepithelial neoplasia.

- Known or suspected human immunodeficiency virus (HIV), hepatitis B surface
antigen-positive status or known or suspected active hepatitis C.

- History of significant cardiovascular, neurological, endocrine, gastrointestinal,
respiratory, or inflammatory illness including but not limited to congestive heart
failure (NYHA Class 3 or 4), unstable angina; cardiac arrhythmia, recent(within past
6 months) myocardial infarction or stroke; uncontrolled hypertension; diabetes
mellitus with > 2 episodes of ketoacidosis in the preceding 12 months, COPD requiring
> 2 hospitalizations in preceding 12 months

- QTcF > 480 msec, family or personal history of long QTc syndrome or ventricular
bigeminy; previous history of drug-induced QTc prolongation or the need for
medications known or suspected of producing prolonged QTc intervals on ECG

- Documented plasma cell leukemia or known amyloidosis.

- Known hypersensitivity to thalidomide or lenalidomide.

- History of erythema nodosum characterized by desquamating rash while taking
thalidomide or similar drugs.

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Establish optimal dose of ACY-1215 in combination with lenalidomide and dexamethasone

Outcome Description:

Determine maximum tolerated dose (MTD) of combination therapy. Patients will be assessed for dose-limiting toxicities (DLT) at each visit during Cycle 1.

Outcome Time Frame:

Upon completion of a 28 day treatment cycle

Safety Issue:


Principal Investigator

Noopur Raje, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Massachusetts General Hospital


United States: Food and Drug Administration

Study ID:




Start Date:

April 2012

Completion Date:

October 2014

Related Keywords:

  • Multiple Myeloma
  • Multiple Myeloma
  • Relapsed
  • Refractory
  • Histone deacetylase inhibitors
  • Lenalidomide
  • Revlimid
  • Dexamethasone
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



Massachusetts General Hospital Boston, Massachusetts  02114-2617
UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina  
Sarah Cannon Research Institute Nashville, Tennessee  37203
Fred Hutchinson Cancer Research Institute Seattle, Washington  98109